Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Progression02:07

Tumor Progression

3.1K
3.1K
Tumor Progression02:07

Tumor Progression

6.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.2K
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

9.0K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
9.0K
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

5.9K
5.9K
Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

2.0K
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
2.0K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Radiological and FDG-PET imaging features of Epstein-Barr virus-positive primary central nervous system lymphomas.

Journal of neurology·2026
Same author

Clinical responses to trastuzumab deruxtecan in molecularly defined ependymoma.

NPJ precision oncology·2026
Same author

Development and preclinical evaluation of a hybrid stereoelectroencephalographic-laser depth electrode for magnetic resonance imaging-guided interstitial thermal therapy in drug-resistant epilepsy.

Epilepsia·2026
Same author

Early brain biopsy in neurological diseases of unknown etiology improves functional outcome.

European journal of internal medicine·2026
Same author

Prognostic factors in adult patients with medulloblastoma.

Neuro-oncology practice·2026
Same author

Diagnostic yield and safety of frame-based versus robot-assisted stereotactic brain biopsy: a matched cohort analysis.

Neurosurgical review·2026

Related Experiment Video

Updated: Apr 28, 2026

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

26.0K

IDH mutations: genotype-phenotype correlation and prognostic impact.

Xiao-Wei Wang1, Pietro Ciccarino1, Marta Rossetto1

  • 1Université Pierre et Marie Curie-Paris 6, Centre de Recherche de l'Institut du Cerveau et de la Moëlle épinière (CRICM) UMR-S975, 75013 Paris, France ; INSERM U 975, 75013 Paris, France ; CNRS, UMR 7225, 75013 Paris, France.

Biomed Research International
|May 31, 2014
PubMed
Summary
This summary is machine-generated.

Isocitrate Dehydrogenase (IDH) mutations are common in gliomas and impact prognosis. IDH mutations are nearly constant in 1p19q codeleted tumors, defining distinct prognostic subgroups in gliomas.

More Related Videos

A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas
06:27

A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas

Published on: May 9, 2025

1.3K
Quantitative Immunohistochemistry of the Cellular Microenvironment in Patient Glioblastoma Resections
05:45

Quantitative Immunohistochemistry of the Cellular Microenvironment in Patient Glioblastoma Resections

Published on: July 31, 2017

9.2K

Related Experiment Videos

Last Updated: Apr 28, 2026

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

26.0K
A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas
06:27

A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas

Published on: May 9, 2025

1.3K
Quantitative Immunohistochemistry of the Cellular Microenvironment in Patient Glioblastoma Resections
05:45

Quantitative Immunohistochemistry of the Cellular Microenvironment in Patient Glioblastoma Resections

Published on: July 31, 2017

9.2K

Area of Science:

  • Neuro-oncology
  • Genomics
  • Cancer research

Background:

  • Isocitrate Dehydrogenase (IDH) mutations are frequent in gliomas, occurring early in gliomagenesis.
  • IDH mutations are the most common genomic alteration in gliomas, present in approximately 40% of cases.
  • Understanding IDH mutation's role is crucial for glioma classification and treatment.

Purpose of the Study:

  • To investigate the association between IDH mutations and 1p19q codeletion in a large glioma cohort.
  • To analyze the distribution of specific IDH1 and IDH2 mutations across different glioma subtypes.
  • To define distinct prognostic subgroups based on IDH mutation and 1p19q codeletion status.

Main Methods:

  • Analysis of 1305 glioma samples.
  • Genomic profiling for IDH1/2 mutations and 1p19q codeletion.
  • Statistical analysis to determine prognostic significance and genotype-phenotype correlations.

Main Results:

  • IDH mutation is nearly constant in 1p19q codeleted gliomas.
  • Distinct patterns of IDH1(R132H), IDH1(nonR132H), and IDH2 mutations were observed in astrocytic, mixed, and oligodendroglial tumors.
  • IDH mutation was confirmed as an independent prognostic factor for favorable outcomes (HR=0.358).
  • Three distinct prognostic subgroups were identified: 1p19q codeleted and IDH mutated, IDH mutated (often TP53 mutated), and neither alteration.

Conclusions:

  • IDH mutation status, in conjunction with 1p19q codeletion, refines glioma classification.
  • Specific IDH mutations show differential distribution, providing insights into glioma subtypes.
  • IDH mutation is a significant independent predictor of better prognosis in gliomas.